Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of three monoclonal antibody injections, indicating a significant advancement in its oncology pipeline [1][2][3] Group 1: SHR-8068 Injection - SHR-8068 is a fully human anti-CTLA-4 monoclonal antibody aimed at enhancing anti-tumor immune effects, with a total R&D investment of approximately 21.35 million yuan [1] - Currently, there are two similar products approved globally, with combined sales of approximately 3.271 billion USD in 2024 [1] Group 2: Adebali Injection - Adebali injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity, with a total R&D investment of about 90.13 million yuan [2] - The product was approved for use in first-line treatment of extensive-stage small cell lung cancer in March 2023, and similar products have a projected global sales of approximately 9.648 billion USD in 2024 [2] Group 3: Bevacizumab Injection - Bevacizumab is a humanized anti-VEGF monoclonal antibody, with a total R&D investment of around 34.49 million yuan [3] - The global sales forecast for Bevacizumab in 2024 is approximately 5.655 billion USD, indicating a strong market presence [3]